Our news
NeoPhore presented preclinical data from our PMS2 program at the AACR Annual Meeting, San Diego, 5 - 10 April 2024.
The NeoPhore team attended the American Association for Cancer Research Annual Meeting in San Diego, 5 - 10 April 2024. In collaboration with The…
NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline
NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline • Italian investors, NE…
NeoPhore presented a first disclosure of NP1867 at AACR-NCI-EORTC Conference in Boston, USA
On Saturday October 14th, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston, USA NeoPhore presented a first…
NeoPhore signs research collaboration with The Institute of Cancer Research, London
London, UK, 18 April 2023, – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has signed a strategic c…
Other news
BioCentury's Emerging Company Profile
CEO Jeff Roix spoke to BioCentury about how NeoPhore Ltd is developing small molecules to inhibit DNA mismatch repair (MMR) and create a pool of…
‘Big place’ for small-molecule booster drugs in cancer immunotherapy, says NeoPhore CEO
APM Health: Interview with CEO, Jeff Roix
NeoPhore Enters Immuno-Oncology Fray With DNA-Repair Technology
Scrip Emerging company profile: UK-based NeoPhore, founded in 2017, is developing novel cancer therapies based on DNA-repair technology. The company…